Composition for reducing intraocular pressure, for local use

 

The invention relates to the field of medicine and relates to a composition for topical application, reducing intraocular pressure, comprising the antagonist of angiotensin II, boric acid and ethylenediaminetetraacetic acid. The composition has a high activity. 4 C. and 12 C.p. f-crystals, 5 PL.

Description text in facsimile form (see graphic part).

Claims

1. Composition for topical application, reducing intraocular pressure, comprising the antagonist of angiotensin II following General formula, or its pharmaceutically acceptable salt, or its derivative

where R1represents a group of the following structure (Ia), (Ib), (Ic), (Id), (Ie) or (If):

boric acid and ethylenediaminetetraacetic acid.

2. Composition under item 1, in which R1represents a group of structure (Ia), (Ib) or (Ic).

3. Composition under item 1, in which the compound of General formula (I) represents the soy is th acid and 2-ethoxy-1-[2-(1H-tetrazol-5-yl)diphenyl-4-yl]methyl-1H-benzimidazole-7-carboxylic acid.

4. Composition according to any one of paragraphs.1-3, further comprising a preservative.

5. The composition according to p. 4, in which the specified preservative is a paraben.

6. The means for lowering the intraocular pressure for the local administration, including the antagonist of angiotensin II following General formula (I) or its pharmaceutically acceptable salt, or a derivative thereof:

where R1represents a group of structure (Ia), (Ib), (Ic), (Id), (Ie) or (If):

boric acid and ethylenediaminetetraacetic acid.

7. Means on p. 6, in which R1represents a group of structure (Ia), (Ib) or (Ic).

8. Means on p. 6, where the compound of General formula (I) is a compound selected from 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}Mei-5-carboxylic acid and 2-ethoxy-1-[2-(1H-tetrazol-5-yl)diphenyl-4-yl]methyl-1H-benzimidazole-7-carboxylic acid.

preservative is a paraben.

11. A method of reducing intraocular pressure, which includes the introduction of a warm-blooded animal a composition according to any one of paragraphs.1-5, containing a pharmaceutically effective amount of an antagonist of angiotensin II General formula (I), as defined in paragraph 1.

12. The method according to p. 11, where warm-blooded animal is a human.

13. The method according to p. 11 or 12, where the intraocular pressure is increased at the expense of glaucoma or ocular hypertension.

14. Composition according to any one of paragraphs.1-5, containing antagonist of angiotensin II General formula (I), as defined in paragraph 1, used for getting medicines for lowering intraocular pressure.

15. The composition according to p. 14, where the intraocular pressure is high due to glaucoma or intraocular hypertension.

16. The application of a combination of an antagonist of angiotensin II General formula (I), as defined in paragraph 1, boric acid and ethylenediaminetetraacetic acid to obtain drugs to lower intraocular pressure.

 

Same patents:

The invention relates to the field of medicine and organic chemistry and relates to new derivatives of prostaglandin F-type used as an ocular hypotensive drugs, as well as to a method of treatment of glaucoma with their help, ophthalmic solutions and kits comprising these solutions

The invention relates to new indole derivative of the formula I

< / BR>
where R denotes ethyl or 2,2,2-triptorelin group; Y is hydroxy or pivaloyloxy; the carbon atom marked with the symbol (R) is the carbon atom in (R)-configuration, or its pharmaceutically acceptable salts

The invention relates to medicine, namely to ophthalmology, and for the treatment of patients with open-angle glaucoma with normalized intraocular pressure

The invention relates to the field of ophthalmology

The invention relates to new guanidinium heterocyclic compounds of the formula (I), where R1denotes H, alkyl or is absent when R1missing link (a) is a double bond, D represents CR2, R2selected from H, alkyl, halogen, or, when is a CR3D can be N, denotes NR9, CR3=CR8, CR3, S, where R9denotes H, alkyl, alkenyl or quinil and where R3and R8selected from H, alkyl, alkenyl, quinil or cyano, R4, R5, R6each independently selected from H, alkyl, alkenyl, quinil, cyano, halogen or NH-C(= NR10)OTHER11(guanidine), R10and R11selected from H, methyl and ethyl, and where only one of R1, R5and R6is guanidines, R7selected from H, alkyl, alkenyl, quinil and halogen
The invention relates to medicine, in particular to ophthalmology, and for the health of the retina and optic nerve in various pathologies of the eye
The invention relates to medicine, ophthalmology, to methods for treating glaucoma
The invention relates to medicine, in particular to ophthalmology, and can be used in the treatment pseudophoenix diseases of the orbit

The invention relates to medicine, in particular to ophthalmology, and can be used as ophthalmic medicines for the treatment of diseases and injuries of the cornea
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of patients with diabetic retinopathy
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of postinflammatory bullous keratopathy

The invention relates to medicine, namely to ophthalmology, and for the treatment of edematous maculopathy
The invention relates to medicine, namely to ophthalmology, and for the prevention of postoperative complications antiglaucomatous surgery
The invention relates to medicine, namely to ophthalmology, and for the treatment of endocrine ophthalmopathy

The invention relates to medicine, to the agent for the prevention or treatment of diseases associated with excessive proliferation of the epithelial pigment cells of the retina, such as proliferative vitreoretinopathy, and includes as the active ingredient N-(3,4-dimethoxycinnamoyl) Anthranilic acid of formula I or its pharmaceutically acceptable salt
The invention relates to medicine, namely to ophthalmology, and for the treatment of degenerative diseases of the retina
The invention relates to medicine, namely to ophthalmology, and for the correction of functional disorders of the visual analyzer

The invention relates to medicine, namely to the development of compositions of the solutions used during operations on the “open” heart

The invention relates to the creation of hepatoprotective tools
Up!